Delineating the therapeutic effect of a novel BBB-penetrable ppar agonist on chronic outcomes following age-related repetitive mild TBI

The Roskamp Institute, Inc. received a $3.27 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) awarded on September 15, 2025, with performance extending through September 14, 2029. The award funds research to delineate the therapeutic effects of a novel blood-brain barrier (BBB)-penetrable peroxisome proliferator-activated receptor (PPAR) agonist on chronic outcomes following age-related repetitive mild traumatic brain injury (TBI). This basic and applied research initiative addresses critical health challenges relevant to military service members and veterans by investigating potential therapeutic interventions for TBI-related neurological complications.

As a specialized biotechnology research organization headquartered in Sarasota, Florida, the Roskamp Institute will conduct this hypothesis-driven research project leveraging its established expertise in neurological disorders and traumatic brain injury investigations. The research deliverables will contribute to the Military Medical Research and Development program's broader objective of transforming healthcare for military personnel through innovative biomedical research and the development of novel therapeutic interventions, consistent with the program's support for advanced research spanning basic through clinical applications with typical award periods of three to four years.